PGxAI Company Profile

Background

Overview

PGxAI is a pioneering company specializing in AI-driven pharmacogenetics, aiming to revolutionize precision medicine by leveraging genetic data to personalize drug therapies. Founded in 2023 and headquartered in Palo Alto, California, PGxAI integrates advanced artificial intelligence with real-world evidence to enhance treatment outcomes and minimize adverse drug reactions.

Mission and Vision

The company's mission is to accelerate the adoption of precision medicine by delivering AI-driven pharmacogenomic insights that reduce adverse events, optimize therapy choices, and ultimately improve patient outcomes. PGxAI envisions a healthcare landscape where every patient receives personalized treatment tailored to their unique genetic makeup, ensuring the most effective and safest therapies.

Primary Area of Focus

PGxAI focuses on developing AI-powered solutions that analyze genetic data to inform drug selection, dosage optimization, and management of drug interactions. By automating complex pharmacogenetic analyses, the company aims to integrate personalized medicine into routine clinical practice, thereby enhancing therapeutic effectiveness and patient safety.

Industry Significance

In the realm of precision medicine, PGxAI stands out by combining generative AI models with extensive pharmacogenomic data. This integration allows for real-time, personalized treatment recommendations, addressing a critical need in healthcare to reduce adverse drug reactions and improve patient outcomes.

Key Strategic Focus

Core Objectives

• Personalized Treatment: Utilize AI to tailor drug therapies based on individual genetic profiles, enhancing efficacy and safety.

• Adverse Event Reduction: Leverage pharmacogenomic insights to minimize adverse drug reactions, a leading cause of morbidity and mortality.

• Clinical Integration: Seamlessly incorporate AI-driven pharmacogenetic analyses into clinical workflows, facilitating widespread adoption.

Areas of Specialization

• Pharmacogenomics: Studying how genetic variations affect drug response to inform personalized treatment plans.

• AI and Machine Learning: Developing advanced algorithms to analyze complex genetic and clinical data for actionable insights.

• Clinical Decision Support: Providing healthcare professionals with AI-driven tools to enhance decision-making processes.

Key Technologies Utilized

• Generative AI Models: Employing large language models to interpret complex pharmacogenomic data.

• Multi-Omics Data Integration: Combining genetic, proteomic, and clinical data to provide comprehensive treatment recommendations.

• Real-Time Data Processing: Utilizing advanced computational infrastructure to deliver timely insights within clinical settings.

Primary Markets Targeted

• Healthcare Providers: Hospitals and clinics seeking to implement personalized medicine strategies.

• Diagnostic Laboratories: Labs aiming to offer comprehensive pharmacogenomic testing services.

• Clinical Research Organizations (CROs): Organizations conducting clinical trials requiring efficient patient stratification.

• Pharmaceutical Companies: Biopharma firms interested in integrating pharmacogenomic data into drug development processes.

Financials and Funding

Funding History

PGxAI has secured funding through strategic partnerships and investments, including a notable seed funding round in December 2024 led by ATEM Capital Fund LP.

Total Funds Raised

The company has raised a total of $1.5 million in funding to date.

Notable Investors

• ATEM Capital Fund LP: A New York-based venture capital firm specializing in life sciences innovation.

Utilization of Capital

The raised capital is intended to support the development and deployment of PGxAI's AI-driven pharmacogenetic platform, including the expansion of therapeutic coverage, enhancement of AI models, and integration with healthcare systems.

Pipeline Development

Key Pipeline Candidates

• Sirius: Launched in July 2024, Sirius is PGxAI's first AI model with 300,000 parameters, delivering five times the drug-gene coverage of top competitors.

• Vega: Released in December 2024, Vega is an advanced AI model with 10 billion parameters, achieving seventy times the coverage of traditional pharmacogenetic panels.

Stages of Development

• Sirius: Successfully launched and integrated into clinical settings, providing actionable pharmacogenomic insights.

• Vega: Currently in deployment, offering expanded drug-gene coverage and enhanced predictive capabilities.

Target Conditions

Both models aim to address a wide range of conditions, including oncology, cardiology, psychiatry, and other therapeutic areas where personalized medicine can significantly improve patient outcomes.

Anticipated Milestones

• Sirius: Ongoing validation studies to assess real-world impact on patient outcomes.

• Vega: Expected to expand therapeutic coverage and integrate additional omics data layers in future iterations.

Technological Platform and Innovation

Proprietary Technologies

• LENSai™: A patented AI model developed by BioStrand, integrated into PGxAI's platform to enhance pharmacogenomic analyses.

Significant Scientific Methods

• Multi-Omics Integration: Combining genetic, proteomic, and clinical data to provide comprehensive treatment recommendations.

• Generative AI Models: Utilizing large language models to interpret complex pharmacogenomic data.

AI-Driven Capabilities

• Real-Time Data Processing: Delivering timely pharmacogenomic insights within clinical workflows.

• Automated Pharmacogenomic Guidelines: Generating near-real-time medication guidance based on the latest clinical evidence.

Leadership Team

Mike Zack, MD, PhD – CEO & Co-Founder

Dr. Zack is a pioneering physician-scientist and entrepreneur specializing in AI-driven precision medicine and multi-omics technologies. With over a decade of experience, he co-founded PGxAI and leads the company's strategic direction. His research has significantly impacted pharmacogenomics and personalized medicine.

Allan Gobbs – Executive Chairman & Co-Founder

Mr. Gobbs is a venture capitalist and deep-tech entrepreneur with extensive experience in life sciences innovation. He co-founded PGxAI and serves as the Executive Chairman, guiding the company's growth and strategic partnerships.

Alex Raud – VP of Development

Mr. Raud brings over 14 years of experience in tech development, including significant contributions at Intel Corporation. As VP of Development at PGxAI, he oversees the technical development of the company's AI models and platform.

Danil Stupichev – VP of Research

Mr. Stupichev is a bioinformatics expert specializing in machine learning-driven oncology solutions and multi-omics data analysis. He leads PGxAI's research initiatives, focusing on integrating high-throughput genomics and advanced computational methodologies.

Russ Altman, MD, PhD – Scientific Advisor

Dr. Altman is a professor at Stanford University with expertise in bioengineering, genetics, and biomedical data science. He advises PGxAI on the application of computing to problems relevant to medicine, particularly in understanding drug action at various levels.

Emily Chen, PhD – Scientific Advisor

Dr. Chen is the Senior Director at Thermo Fisher Precision Medicine Science Center. She provides strategic guidance to PGxAI on precision medicine and pharmacogenomics, leveraging her extensive experience in molecular pathology and proteomics.

Terry Robins, PhD – Business Advisor

Dr. Robins is the Senior Director of Clinical Affairs at Abbott, with over two decades of experience in global clinical trials and diagnostic technologies. He advises PGxAI on clinical strategy and regulatory affairs.

Nisha Talagala – Strategic AI Advisor

Ms. Talagala is the CEO and founder of AIClub.World and has over 20 years of expertise in enterprise software development and AI strategy. She advises PGxAI on AI integration and operational machine learning.

Leadership Changes

As of September 2025, there have been no leadership changes reported.